Atosiban Versus Placebo in the Treatment of Late Threatened Pre-term Birth

PHASE4CompletedINTERVENTIONAL
Enrollment

760

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
Preterm Birth
Interventions
DRUG

Atosiban

atosiban i.v. administred for 48 hours. The medication will be administered by a bolus injection of 6.75 mg/0.9 mL in 1 min followed by a continuous infusion of 18 mg/hour for 3 hours followed by a continuous infusion of 6 mg/hour for the remaining 45 hours.

Trial Locations (1)

1105 AZ

Amsterdam University Medical Centres, location AMC, Amsterdam

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Nottingham University Hospitals NHS Trust

OTHER

collaborator

Amphia Hospital

OTHER

collaborator

St. Antonius Hospital

OTHER

collaborator

Deventer Ziekenhuis

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Flevoziekenhuis

OTHER

collaborator

Franciscus Gasthuis

OTHER

collaborator

Gelre Hospitals

OTHER

collaborator

Groene Hart Ziekenhuis

OTHER

collaborator

Isala

OTHER

collaborator

Leiden University Medical Center

OTHER

collaborator

Martini Hospital Groningen

OTHER

collaborator

Maxima Medical Center

OTHER

collaborator

Frisius Medisch Centrum

OTHER

collaborator

Haaglanden Medical Centre

OTHER

collaborator

Maastricht University Medical Center

OTHER

collaborator

Medisch Spectrum Twente

OTHER

collaborator

OLVG

NETWORK

collaborator

Radboud University Medical Center

OTHER

collaborator

Rijnstate Hospital

OTHER

collaborator

Spaarne Gasthuis

OTHER

collaborator

Tergooi Hospital

OTHER

collaborator

University Medical Center Groningen

OTHER

collaborator

UMC Utrecht

OTHER

collaborator

Diakonessenhuis, Utrecht

OTHER

collaborator

Ziekenhuisgroep Twente

OTHER

collaborator

Zuyderland Medical Centre

OTHER

collaborator

National Maternity Hospital, Ireland

OTHER

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT05693688 - Atosiban Versus Placebo in the Treatment of Late Threatened Pre-term Birth | Biotech Hunter | Biotech Hunter